| Verified against primary record | |
| Structured content model | Core elements, essential for clinical management, staging or prognosis and requiring a defined evidence level, plus non-core elements[1] |
|---|---|
| International harmonisation goal | One internationally agreed dataset per tumour type, to replace duplicated national development and support comparison[2] |
| Staging edition divergence | A protocol posted April 2026 stages to the eighth edition while a dataset published May 2026 stages to the ninth[3] |
| Independently reported | |
| Second review | Clinically significant discrepancies affecting care were found in 11.5 per cent of 1,970 referred breast cases re-reviewed at one centre[4] |
| Bands apply only to the rows beneath them. The re-review figure is a discrepancy rate, not the proportion of patients whose management actually changed, and describes referral review within one country. | |
Pathology reports are the laboratory’s account of what tissue removed from a patient turned out to be. For a patient treated abroad the report is the document that determines what treatment should follow, and whether it can be acted on at home depends on more than translation.
What a structured report must contain
The international body that develops cancer reporting datasets splits every dataset into core elements, defined as essential for clinical management, staging or prognosis and requiring a defined level of evidence on a published hierarchy for tumour pathology, and non-core elements, which have unanimous authoring-committee support but lack that evidence level. The evidence hierarchy is mapped to the chapters of the international tumour classification; datasets are committed to publication in step with updates to that classification; a change to a dependent publication such as a staging system triggers new dataset development; and a pathological staging category would normally be a core element.[1]
That body was formed in 2011 by the pathology colleges of Australasia, the United Kingdom, the United States and Canada together with a Canadian cancer partnership, with the European society joining in 2013. Its stated aim is to replace duplicated national dataset development with one internationally agreed dataset per tumour type, supporting comparison and benchmarking and helping countries that cannot build their own.[2] The cross-border intelligibility of histology reports is therefore an explicit goal of the field’s own institutions rather than a complaint invented here.
A national dataset shows what this looks like in practice. One published in May 2026 for nodal excisions associated with head and neck carcinoma mandates core items including specimens by side and node level, histological type, grade where applicable, largest metastasis and largest involved node dimensions, soft-tissue metastasis, extranodal extension subcategorised by size, non-lymphatic structures involved and the nodal stage, with a completeness expectation of at least 95 per cent for the national cancer dataset, while operative procedure, margin status, node ratio, block key and ancillary studies are non-core. It also sets coding, node-yield and turnaround expectations.[5]
The staging edition problem
Staging is where a foreign report most easily becomes uninterpretable, and the divergence is current rather than historical. The international staging system’s ninth edition was published in 2025, with the publishing union recommending it take effect from 1 January 2026, the eighth having been published in 2016; change management runs through an evaluation committee, and interim revisions are handled by explicit labelling.[6] Yet a cancer protocol posted in April 2026 by one national college states its standard as the eighth edition,[3] while the national dataset published in May 2026 by another stages to the ninth and allows the eighth to be recorded as a non-core item for audit continuity.[5]
For the same tumour in the same months, therefore, a report from one country can carry stage categories defined by a different edition from a report in another. The writeable conclusion is narrow and important: a stage on a foreign histology report cannot be interpreted without knowing which edition and which publishing body produced it, and reports do not always say. Staging is not a single global standard, and the editions of the two main publishing bodies are not numbered in step.
The diagnostic vocabulary is better harmonised than the staging. The international tumour classification series is described by its publisher as the standard for the diagnosis of tumours and as an international standard for everyone involved in cancer care or research, with pathologists, surgeons, oncologists, radiologists, researchers and registrars as its named audience.[7] So the name of the disease on a foreign report is more likely to travel intact than the number beside it.
What re-review finds
On second review of 1,970 referred breast pathology cases at one tertiary centre, clinically significant discrepancies, defined as disagreement that affected patient care, were found in 226 cases, 11.47 per cent.[4] Two cautions apply. The figure is a discrepancy rate rather than a count of patients whose management actually changed, and the study describes referral review within one health system, so it is suggestive for cross-border re-review rather than direct evidence of it. No study was located measuring discrepancy rates in second reads of pathology performed abroad for medical travel patients.
Practical consequences for a returning patient
Three things follow for someone who has had tissue removed abroad. A report that does not state the dataset or protocol it follows cannot be checked for completeness against a core-element list. A stage quoted without its edition and publishing body is not actionable. And where the home system re-reviews the material, a differing opinion is a normal feature of second review rather than evidence that the original was wrong, which is why the blocks and slides themselves, not only the report, are worth asking the foreign laboratory to release.
One sourcing limitation is worth recording. Whether synoptic reporting is a condition of a particular laboratory accreditation, and under which checklist item, could not be verified from the accrediting college’s own frequently-asked-questions pages, which returned question lists without answers. The only accreditation fact verified from that college’s own material is that elements marked optional in its protocols are not required for accreditation, and that the protocol consulted carries a required-use date of January 2027.[3][8]
See also
- Operative Reports, the companion document describing what was removed
- Radiology Reports, where the images behind the report usually do not travel
- Cancer Treatment Abroad, the setting in which staging edition matters most
- Second Medical Opinions, the formal route to a re-review of the material
References
- International Collaboration on Cancer Reporting. Dataset development. Page last modified 22 June 2026; development guidelines version 3.8, June 2026. Verified against primary record: the page was opened and the core and non-core definitions, the evidence hierarchy, the synchronisation commitment and the staging dependency read. Retrieved 10 October 2026.
- International Collaboration on Cancer Reporting. How the ICCR started. Verified against primary record: the page was opened and the founding bodies, dates and stated aims read. Retrieved 10 October 2026.
- College of American Pathologists. Protocol for the examination of specimens from patients with cancers of the oral cavity, version 4.3.0.0. Posted April 2026; accreditation required-use date January 2027. Verified against primary record: the protocol was opened and its element categories, synoptic summary structure and stated staging edition read. Retrieved 10 October 2026.
- Khazai L, Middleton LP, Goktepe N, Liu BT, Sahin AA. Breast pathology second review identifies clinically significant discrepancies in over 10% of patients. Journal of Surgical Oncology 2015;111(2):192-197. Independently reported: the institutional publication record was opened and the case count and discrepancy proportion read; the journal full text was not read. Retrieved 10 October 2026.
- Thavaraj S, Walsh H, Wright S, Sandison A. Dataset for the histopathological reporting of nodal excisions and neck dissection specimens associated with head and neck carcinomas. Royal College of Pathologists, document G112 version 2, May 2026. Verified against primary record: the dataset was opened and the core and non-core item lists, the completeness expectation and the staging edition provisions read. Retrieved 10 October 2026.
- Union for International Cancer Control. TNM: publications and resources. Page last updated 16 July 2026. Verified against primary record: the page was opened and the ninth edition publication year, the recommended effective date, the eighth edition year and the change-management arrangements read. The page does not mention the American publishing body, so it is not cited for any statement about alignment between the two. Retrieved 10 October 2026.
- WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours, WHO Classification of Tumours, fifth edition, volume 8. International Agency for Research on Cancer, 2022, ISBN 978-92-832-4512-4. Verified against primary record: the publication page was opened and the publisher’s description of the series and its audience read. Retrieved 10 October 2026.
- College of American Pathologists. Cancer protocols frequently asked questions. Published and last modified 11 June 2026. Independently reported: the page was opened and returned only the list of questions without answers, so no accreditation requirement, checklist item or standard number is attributed to it here. Retrieved 10 October 2026.
Sourcing note: the staging edition divergence is reported from the two documents themselves, each dated, rather than from any commentary on it. The staging publishing body’s own page does not mention the other main publishing body, so no claim is made here about whether their edition numbering aligns. The re-review figure is presented as a discrepancy rate, which is what the source measured, and no figure was located for re-review of pathology performed abroad.